SMITHS-DETECTION
13.4.2021 13:02:12 CEST | Business Wire | Press release
Smiths Detection, a global leader in threat detection and security screening technologies, today announces that its BioFlash® Biological Identifier has been successfully used by the University of Maryland, Baltimore County (UMBC) to identify airborne SARS-CoV-2 inside their campus in real-time at the point of testing.
As part of their mitigation strategy for COVID-19, UMBC’s Environmental Safety and Health (ESH) team have been using BioFlash across the campus. In one instance, the airborne detector was deployed to help the campus community safely re-enter a research facility after a person working there tested positive. After multiple tests performed on the BioFlash ruled-out the presence of airborne SARS-CoV-2, the ESH team deemed the facility contamination-free, allowing staff and students to safely return and research to continue without significant pause.
In a separate instance, in a collaborative effort with the UMBC Sports Medicine Department, a test conducted in a team locker room resulted in a positive environmental detection on the BioFlash. This detection ultimately led UMBC to test all people present for COVID-19, identifying three infected individuals. This helped prevent further spread of the virus.
“We are delighted to see what we believe is a world-first for our technology. BioFlash, with its real-time results capability, has been used by UMBC in a real-world setting to successfully confirm the presence or absence of COVID-19 in the air and inform health and safety protocols,” said Smiths Detection President Roland Carter. “We have been working incredibly hard to provide a tool that will support the ongoing fight against COVID-19, and these applications demonstrate the role BioFlash can play in virus mitigation strategies.”
“The BioFlash system has helped us to prevent the spread of the virus in our on-campus community. We are also pleased that this tool to protect the health and safety of people on our campus is easy to use and environmentally friendly,” said Lynne Schaefer, UMBC Vice President for Administration and Finance . “We will be using this solution as part of a larger mitigation strategy, alongside other important tools like sanitation, masks, regular testing, physical distancing, and symptom monitoring.”
BioFlash works by collecting and analysing air samples using sensitive, selective and rapid detection technology to identify the presence of dangerous pathogens onsite without the need to involve a laboratory. Following successful internal testing, Smiths Detection has been engaged in various external studies to further verify the SARS-CoV-2 detection capability, including working with the USAMRIID, which verified that BioFlash could identify SARS-CoV-2 in a laboratory setting.
The BioFlash Biological Identifier is available now.
ENDS
About BioFlash Biological Identifier
The BioFlash ® Biological Identifier is a bio-aerosol collection and identification system that provides rapid, sensitive and specific identification of various pathogens including viruses, toxins and bacteria. The BioFlash has been commercially available for over 10 years and is currently used by US government and commercial clients for a number of applications.
About Smiths Detection
Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for aviation, ports and borders, defence and urban security markets. Our experience and history across more than 40 years at the frontline enables us to deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.
For more information visit http://www.smithsdetection.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005091/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity30.1.2026 07:00:00 CET | Press release
Results from a global survey of over 4,300 women across five continents presented at IMCAS 2026 reveal a knowledge gap on the impact of menopause on the skin, despite women experiencing around three skin changes during menopause1 Galderma will also host a symposium delving into the challenges and science behind menopause-related skin changes and aesthetic solutions at the congress Galderma is committed to raising awareness of the impact of menopause on the skin, fostering meaningful dialogue between patients and healthcare professionals, and advancing science-backed solutions by incorporating menopausal status into all injectable aesthetics clinical trials Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learne
Andersen Consulting styrker sine cybersikkerhedskompetencer med tilføjelsen af RedLegg30.1.2026 00:18:00 CET | Pressemeddelelse
Andersen Consulting styrker sit cybersikkerhedsudbud gennem en samarbejdsaftale med RedLegg, der er et cybersikkerhedsfirma med speciale i administreret trusselsdetektion og rådgivningsydelser. RedLegg blev grundlagt i 2008 og har hovedsæde i USA. RedLegg tilbyder skræddersyede cybersikkerhedsløsninger med fokus på risikominimering, administrerede sikkerhedstjenester og penetrationstest. Virksomhedens ydelser omfatter blandt andet managed detection and response (MDR), hændelsesrespons, udvikling af sikkerhedspolitikker samt virtuel CISO-rådgivning. RedLegg betjener mellemstore virksomheder inden for finans, forsikring, jura og sundhedssektoren og kombinerer automatisering, trusselsintelligens og et dedikeret Security Operations Center (SOC) for at hjælpe organisationer med at effektivisere deres cybersikkerhedsoperationer og opbygge langsigtet modstandsdygtighed. "Vores fokus har altid været at hjælpe kunder med at skære støjen fra og prioritere det, der virkelig betyder noget – nemlig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
